Clinical Trial Update: A Phase 2 Study of Ivosidenib in Previously Treated Japanese Subjects With Nonresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation [Phase 2]

View source ↗

Summary

Phase 2 study of Ivosidenib in Japanese patients with nonresectable or metastatic IDH1-mutant cholangiocarcinoma. Results were posted on 2025-12-09.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma

Drugs mentioned

• Ivosidenib (ivosidenib)

Snippet

Sponsor: Servier | Conditions: Cholangiocarcinoma Non-resectable, Cholangiocarcinoma Metastatic | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-12-09